Biogen has taken up an option on a technology developed by Denali that it thinks could help improve the safety and efficacy of amyloid-targeting drugs for Alzheimer’s disease. The technology ...

Despite past failures, Denali's extensive pipeline and solid financial runway make it a compelling buy at current low stock ...

Biogen will make an upfront payment to Denali of $560 million and make a $465 million equity investment in Denali from the purchase of 13.3 million newly issued shares of Denali common stock at ...

Denali and partner Biogen BIIB have collaborated to develop and commercialize small molecule inhibitors of LRRK2. Biogen is conducting the global phase IIb LUMA study, which is evaluating the ...

BIIB122/DNL151 (small moleculeLRRK2 inhibitor) for the treatment of Parkinson’s disease (PD) Denali and Biogen are jointly developing LRRK2 small molecule inhibitors. Biogen is leading the ...

Denali Therapeutics shares reversed higher Tuesday ... from prior Phase 1 studies," William Blair's Schram said. She said Biogen and Ionis Pharmaceuticals' approved ALS treatment, Qalsody, also ...

This pilot initiative aims to accelerate the development of rare disease treatments. Denali and Biogen BIIB are jointly evaluating a LRRK2 inhibitor BIIB122/DNL151 in development to treat ...

Biogen's 2025 forecasts hit by declining sales ... sending the latter's stock up 34% in extended trade. January 6, 2025 Denali Therapeutics' ALS drug fails in mid-to-late stage trial Denali ...